The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The study met its primary endpoint and all 11 secondary efficacy endpoints
HYMPAVZI’s safety profile was generally favorable
Captured microbes are then neutralized on engineered microbicidal surfaces
The launch of the study was on the occasion of the International Day of Persons with Disabilities
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
This campaign is to raise awareness about the crucial role helmet usage plays in saving lives
Growing patent filings and tier-2 innovators reflect expanding national research base
Subscribe To Our Newsletter & Stay Updated
